EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Aroa Biosurgery Limited (AROAF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Aroa Biosurgery Limited $0.10, price $0.47, upside -78.8%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · Home Australia

AB Aroa Biosurgery Limited logo Thin data Sep 24, 2026

Aroa Biosurgery Limited

AROAF · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $0.1000 · Strongly overvalued (−78.8%)
✓Quality 61/100
!Expensive Growth (revenue 3y +27.8 %/yr)
!Thin margins · 4.5% net margin (TTM)
!negative free cash flow
!Mixed vs. peers (5/11)
!Narrow moat 40/100
!Evidence only low, so the estimate is less certain
!Weak on past: 19 out of 100
Watch Aroa Biosurgery Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.5220 $0.2439 Fair Value $0.1000 Mar 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

18‑month range $0.2439 – $0.5220 · fair‑value band $0.0600 – $0.1200 · the $0.4726 price screens above the $0.1000 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Aroa Biosurgery in your weekly email

Every Wednesday you see whether Aroa Biosurgery is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Show more

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Stock analysis

Aroa Biosurgery Limited (AROAF) currently trades at $0.4726, while our model-based Fair Value estimate is $0.1000, 78.8% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 89/100, which puts the evidence level at low.

Scenario range: $0.0600 (bear) to $0.1200 (bull), the price of $0.4726 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Aroa Biosurgery Limited reported revenue of A$77.0M in FY2025 versus A$20.5M in FY2021, a compound +39.2%/yr. Reported net income was −A$3.5M in FY2025.

Key figures

Market cap $180M · P/E ratio 47.3 · P/S ratio 1.74 · EPS (TTM) $0.0100 · Net margin −4.5% · Return on equity 4.9% · Return on assets (EBIT) −12.2% · Operating margin 12.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −79%, AROAF screens richer than that median.

Fair Value models

Bear $0.0600 Fair Value $0.1000 Bull $0.1200
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.0100 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0800 $0.1100 $0.1700 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.0800 $0.1100 $0.1700 51

Open the full fair value analysis →

Notify me when AROAF reaches fair value

Put AROAF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 61/100

Of which business quality 56 · Market factors (momentum, volatility) 60

Profitability 33
Margins and returns on capital today
Quality Growth 86
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 80
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 47
Calm price path (market factor)
Momentum 62
Price trend over the last 3–12 months (market factor)
52W Momentum 72
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+21.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−70.4% (2021) → −10.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

AROAF screens overvalued: fair value 79% below the price. Compare with Abbott Laboratories, →

Compare Aroa Biosurgery Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 56 · Above median
Fair Value upside −36.7% · Below median
Profitability
Return on equity (TTM) 4.9% · Above median
Return on assets 3.1% · Above median
Net margin (TTM) 4.5% · Below median
Operating margin (TTM) 12.0% · Above median
Growth and dividend
Revenue growth 29.5% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 47.3× · Priciest 25%
P/B 3.07× · Pricier than median
P/S (TTM) 2.50× · Pricier than median
EV/EBITDA 28.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 9
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)19 · sector 11
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aroa Biosurgery Limited · Fair Value
$0.1000 −79%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Aroa Biosurgery Limited Fair Value". https://www.fairvalue-calculator.com/stock/AROAF

Frequently asked questions

Is Aroa Biosurgery Limited (AROAF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.1000 versus the last price from Sep 25, 2026 of $0.4726, about −79% upside (overvalued).
What is the fair value of AROAF?
Our model-based fair value for Aroa Biosurgery Limited is $0.1000 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.4726.
What is the quality score of AROAF?
Aroa Biosurgery Limited has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aroa Biosurgery Limited (AROAF)?
Our model-based price target is the fair value of $0.1000 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.0600, optimistic scenario $0.1200. It is a calculation from audited fundamentals, not an analyst target.
What is the Aroa Biosurgery Limited stock forecast for 2026?
Our models put fair value at $0.1000, about −79% upside versus the last price from Sep 25, 2026 of $0.4726 (overvalued). Cautious scenario $0.0600, optimistic scenario $0.1200. The calculation is refreshed regularly with new filings.
What is the revenue of Aroa Biosurgery Limited (AROAF)?
Aroa Biosurgery Limited reported trailing-twelve-month revenue of about A$104M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Aroa Biosurgery Limited (AROAF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aroa Biosurgery Limited it is $0.1000 per share (as of Sep 24, 2026), against a price of $0.4726. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Aroa Biosurgery Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, AROAF trades above its calculated fair value: price $0.4726, fair value $0.1000, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AROAF?
No. The price is what the market pays today ($0.4726); the fair value is what the company's own numbers justify ($0.1000). For Aroa Biosurgery Limited the two are $0.3726 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aroa Biosurgery Limited worth?
The market values Aroa Biosurgery Limited at about $180M (market capitalisation, as of Sep 24, 2026). Per share that is $0.4726; our models calculate a fair value of $0.1000 per share.
What do the bullish and bearish scenarios say about AROAF?
Our models span a range for Aroa Biosurgery Limited: cautious scenario $0.0600, base $0.1000, optimistic $0.1200 per share (as of Sep 24, 2026, price $0.4726). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AROAF?
Aroa Biosurgery Limited trades at a price-to-earnings ratio of 47.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.1000 is built from several models across several years. Other multiples: P/B 3.1, P/S 2.5, EV/EBITDA 28.6.
How solid is the balance sheet of Aroa Biosurgery Limited (AROAF)?
Balance-sheet figures for Aroa Biosurgery Limited (as of Sep 24, 2026): return on equity 4.9%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is AROAF from its 52-week high?
Aroa Biosurgery Limited trades at $0.4726, about 9% below its 52-week high of $0.5220 and 35% above the low of $0.3500 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1000 is for.
Which stocks are comparable to Aroa Biosurgery Limited?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aroa Biosurgery Limited stock attractive at the current price?
The data as of Sep 24, 2026: price $0.4726, calculated fair value $0.1000 (−79%), Quality Score 61/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AROAF calculated?
We run Aroa Biosurgery Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Aroa Biosurgery Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aroa Biosurgery Limited (AROAF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.4726. Our model-based fair value is $0.1000, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aroa Biosurgery Limited right now?
The price sits above even our optimistic bull case ($0.1200). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.0600 to $0.1200) leaves room in how you read the outcome.

Key figures of Aroa Biosurgery Limited

How large is the market capitalisation of Aroa Biosurgery Limited (AROAF)?
The market capitalisation of Aroa Biosurgery Limited is $180M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aroa Biosurgery Limited (AROAF)?
The price-to-sales ratio of Aroa Biosurgery Limited is 1.74 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aroa Biosurgery Limited (AROAF)?
Earnings per share at Aroa Biosurgery Limited are $0.0100 (price ÷ EPS = P/E 47.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Aroa Biosurgery Limited (AROAF)?
The net margin of Aroa Biosurgery Limited is −4.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aroa Biosurgery Limited (AROAF)?
The return on equity (ROE) of Aroa Biosurgery Limited is 4.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aroa Biosurgery Limited (AROAF)?
On an EBIT basis the return on assets of Aroa Biosurgery Limited is −12.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aroa Biosurgery Limited (AROAF)?
The operating margin of Aroa Biosurgery Limited is 12.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aroa Biosurgery Limited (AROAF)?
Revenue at Aroa Biosurgery Limited is growing +29.5% versus a year earlier (3y avg +27.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Aroa Biosurgery Limited (AROAF) generate?
The free cash flow of Aroa Biosurgery Limited is −A$5.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Aroa Biosurgery Limited in the live analysis

One click puts Aroa Biosurgery Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.